Mitochondrial dynamics refer to the continuous balance between mitochondrial fission (division) and fusion (joining), essential for maintaining mitochondrial morphology, distribution, and quality control. This dynamic process is critical for neuronal health, as neurons are highly energy-demanding cells with specialized axonal and dendritic compartments requiring efficient mitochondrial trafficking and distribution.
Dysregulation of mitochondrial dynamics is a hallmark of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). The balance between fission and fusion determines mitochondrial morphology, which directly impacts cellular energetics, calcium homeostasis, reactive oxygen species (ROS) production, and the ability to clear damaged mitochondria through mitophagy.
| Process |
Key Proteins |
Function |
| Fusion (OMM) |
MFN1, MFN2 |
Outer membrane fusion |
| Fusion (IMM) |
OPA1 |
Inner membrane fusion |
| Fission |
DRP1, FIS1, MFF |
Mitochondrial division |
| Quality Control |
PINK1, Parkin |
Mitophagy initiation |
¶ The Fission and Fusion Cycle
Mitochondrial dynamics operate as a continuous cycle essential for mitochondrial health:
Fusion Process:
- Mitofusins (MFN1, MFN2) mediate outer mitochondrial membrane (OMM) tethering
- OPA1 mediates inner mitochondrial membrane (IMM) fusion
- Matrix contents intermix, allowing complementation of proteins and DNA
- Fusion enables mitochondrial DNA repair, protein exchange, and metabolic complementation
Fission Process:
- DRP1 is recruited from cytosol to OMM via receptor proteins (FIS1, MFF)
- Drp1 oligomerizes into ring-like structures around mitochondria
- GTP hydrolysis drives constriction and division
- Daughter mitochondria can be healthy or damaged
Quality Control:
- Damaged mitochondria fail to fuse and are marked for removal
- PINK1 stabilizes on damaged mitochondrial OMM
- Parkin is recruited to ubiquitinate mitochondrial proteins
- Autophagosomes engulf marked mitochondria (mitophagy)
flowchart TD
A["Healthy Mitochondria"] --> B["MFN1/2 Mediated OMM Fusion"]
B --> C["OPA1 Mediated IMM Fusion"]
C --> D["Matrix Intermixing"]
D --> E["Mitochondrial DNA Repair<br/>Protein Exchange"]
F["Stress/Damage"] --> G["Drp1 Recruitment via MFF/FIS1"]
G --> H["Drp1 Oligomerization"]
H --> I["GTP Hydrolysis-Driven Constriction"]
I --> J["Daughter Mitochondria<br/>Healthy vs Damaged"]
K["Damaged Mitochondria"] --> L["PINK1 Stabilization on OMM"]
L --> M["Parkin Recruitment"]
M --> N["Ubiquitin Tagging"]
N --> O["Autophagosome Recognition"]
O --> P["Lysosomal Degradation"]
Q["AD Pathology"] --> R["Drp1 Hyperactivity"]
Q --> S["Tau-Drp1 Interaction"]
Q --> T["Aβ-Induced Fragmentation"]
U["PD Pathology"] --> V["PINK1 Mutations"]
U --> W["Parkin Loss-of-Function"]
U --> X["MFN2 Dysfunction"]
Y["ALS Pathology"] --> Z["C9orf72 Hexanucleotide Expansions"]
Y --> aa["FUS/TDP-43 Dysregulation"]
aa --> bb["Mitochondrial Fragmentation"]
style R fill:#ffcdd2
style V fill:#ffcdd2
style W fill:#ffcdd2
style Z fill:#ffcdd2
¶ Mitofusins (MFN1 and MFN2)
MFN1 and MFN2 are GTPases located on the OMM that mediate mitochondrial tethering and fusion:
- MFN1: Primarily fusion-competent, higher GTPase activity
- MFN2: Additional roles in mitochondrial transport, ER-mitochondria contacts
- MFN2 mutations cause Charcot-Marie-Tooth disease type 2A
- Both downregulated in AD brain
OPA1 (Optic Atrophy 1) mediates IMM fusion and cristae maintenance:
- Over 8 isoforms generated by alternative splicing
- Proteolytic cleavage regulates fusion competence
- Mutations cause autosomal dominant optic atrophy
- Critical for mitochondrial DNA maintenance
DRP1 (Dynamin-related protein 1) is the master executor of mitochondrial fission:
- Cytosolic protein recruited to mitochondria during fission
- Multiple phosphorylation sites regulate activity (Ser616, Ser637)
- Post-translational modifications: phosphorylation, sumoylation, ubiquitination
- Elevated in AD and correlates with pathology severity
¶ FIS1 and MFF
FIS1 and MFF serve as Drp1 receptors on the OMM:
- MFF is the primary receptor in most tissues
- FIS1 may have additional roles in peroxisome biogenesis
- Both upregulated in neurodegeneration models
DRP1 expression and activity are significantly elevated in AD neurons:
- Post-translational modifications increase Drp1 activity
- Pathological tau directly interacts with Drp1, enhancing fission
- Amyloid-beta upregulates Drp1 expression via oxidative stress
The hyperactive fission creates a vicious cycle:
- Excessive fission produces small, fragmented mitochondria
- Fragmented mitochondria cannot meet neuronal energy demands
- Impaired mitochondrial transport affects synaptic function
- Synaptic loss and cognitive decline result
Pathological tau drives mitochondrial dysfunction through multiple mechanisms:
- Direct interaction with Drp1 enhances its GTPase activity
- Tau accumulation disrupts mitochondrial transport along axons
- Hyperphosphorylated tau reduces MFN2 expression
- Mitochondrial cristae disruption precedes cognitive decline
Aβ oligomers induce mitochondrial fragmentation through:
- Direct interaction with mitochondrial proteins
- Oxidative stress leading to Drp1 activation
- Calcium dysregulation affecting mitochondrial dynamics
- Impaired mitochondrial biogenesis
AD neurons show significantly reduced fusion capacity:
- MFN2 and OPA1 expression decreased
- OPA1 processing altered, reducing fusion-competent isoforms
- ER-mitochondria contacts disrupted
PINK1 and Parkin are central to PD pathogenesis:
- PINK1: Kinase that accumulates on damaged mitochondria
- Parkin: E3 ubiquitin ligase recruited by PINK1
- Together, they initiate mitophagy for quality control
- Autosomal recessive PD: Caused by loss-of-function mutations in either gene
The PINK1/Parkin pathway:
- Mitochondrial damage (complex I inhibition, oxidative stress)
- PINK1 stabilizes on OMM (unable to enter mitochondria)
- Parkin recruited and activated
- Ubiquitination of mitochondrial surface proteins
- Autophagy receptor binding (p62, optineurin)
- Autophagosome engulfment and lysosomal degradation
MFN2 mutations and dysregulation contribute to PD:
- MFN2 polymorphism associated with PD risk
- PINK1 phosphorylates MFN2 to promote mitophagy
- MFN2 downregulation impairs mitochondrial dynamics
- Affects dopaminergic neuron survival specifically
PD neurons show prominent complex I deficiency:
- Environmental toxins (MPTP, rotenone) inhibit complex I
- Mitochondrial DNA mutations accumulate in SNc
- PINK1/Parkin pathway tries to compensate but fails
- Energy crisis leads to dopaminergic neuron loss
The C9orf72 hexanucleotide repeat expansion is the most common genetic cause of ALS:
- Leads to toxic RNA foci and dipeptide repeat proteins
- Disrupts mitochondrial dynamics proteins
- Impairs mitochondrial transport in motor neurons
- Reduces mitochondrial membrane potential
¶ FUS and TDP-43
ALS-associated proteins affect mitochondrial function:
- FUS mutations disrupt mitochondrial DNA maintenance
- TDP-43 pathology affects mitochondrial dynamics genes
- Reduced fusion proteins in ALS motor neurons
SOD1 mutations cause mitochondrial dysfunction:
- Mutant SOD1 accumulates in mitochondria
- Disrupts electron transport chain
- Induces mitochondrial fragmentation
- Triggers apoptotic pathways
| Compound |
Mechanism |
Stage |
| Mdivi-1 |
Inhibits Drp1 GTPase activity |
Preclinical |
| Drp1 siRNA |
Gene silencing |
Research |
| Dynasore |
Inhibits dynamin 1/2 (less specific) |
Research |
| Approach |
Target |
Status |
| MFN1/2 overexpression |
Fusion |
Research |
| OPA1 modulators |
IMM fusion |
Preclinical |
| Natural compounds |
Various |
Research |
| Strategy |
Approach |
Status |
| AAV-Parkin |
Gene therapy |
Clinical trials |
| PINK1 activators |
Small molecules |
Research |
| USP30 inhibitors |
Enhance Parkin function |
Preclinical |
| Compound |
Target |
Status |
| MitoQ |
CoQ10 analog |
Clinical trials |
| MitoVitE |
Vitamin E analog |
Research |
| SS-31 (Bendavia) |
Cardiolipin |
Clinical trials |
| CoQ10 |
ETC complex I |
Clinical trials |
- Reddy PH et al. Mitochondrial Dysfunction in Alzheimer Disease (2021)
- Itoh K et al. Mitochondrial Dynamics in Neurodegenerative Disease (2013)
- Wang X et al. Drp1 Phosphorylation in Neurodegenerative Diseases (2021)
- Chan DC. Mitochondrial Dynamics and Neurodegeneration (2020)
- Pickrell AM et al. Roles of PINK1, Parkin in PD (2015)
- Burte F et al. Disturbed Mitochondrial Dynamics in Neurodegeneration (2015)
- Mitochondrial Dynamics in Brain Cells During Normal and Pathological Aging (2024)
- Longitudinal autophagy profiling reveals sustained mitophagy throughout healthy aging (2024)
- Modulation of Mitochondrial Dynamics by the Angiotensin System in Dopaminergic Neurons (2024)
- SUMOylation modulates mitochondrial dynamics in rotenone model of PD (2024)
- Mitotherapy-Based Approaches towards α-Synucleinopathies (2024)
- Tau pathology drives mitochondrial dysfunction via Drp1 (2023)
- Amyloid-beta induces mitochondrial fragmentation via Drp1 (2022)
¶ Biomarkers and Clinical Relevance
| Biomarker |
Source |
Disease |
Status |
| Drp1 levels |
Blood/CSF |
AD, PD |
Research |
| PINK1 levels |
Blood |
PD |
Research |
| Mitochondrial DNA copies |
Blood |
ALS |
Research |
| Mitophagy markers |
CSF |
PD |
Research |
- Drp1 phosphorylation state (Ser616) as pharmacodynamic marker
- Mitochondrial morphology in patient-derived neurons
- Mitophagy flux measurements
- MitoQ: NCT03821895 (PD), NCT03444220 (AD)
- CoQ10: NCT00740753 (PD), NCT02655312 (AD)
- SS-31 (Bendavia): NCT02240966 (AD)
- AAV-Parkin: Recruiting for PD (NCT02795888)